Anagenics Limited · ASX:AN1

Anagenics — Cellmid — FY2019 Earnings Presentation

22 slides from Anagenics's earnings presentation, Aug 28, 2019

  1. Slide 1: FY2019 Financial Results

    FY2019 Financial Results 28 August 2019 ASX: CDY

  2. Slide 2: Forward looking statements

    Accelerating sales of clinically proven hair loss products in Japan, the USA, China, Australia, Europe and Asia Forward looking statements This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause

  3. Slide 3: Agenda: Sections 1-5

    Section 1: Financial highlights Section 2: Advangen segment report Section 3: Investing in growth Section 4: Lyramid segment report Section 5: Upcoming milestones 3

  4. Slide 4: Section 1: FY2019 Highlights

    SECTION 1: FY2019 HIGHLIGHTS 4

  5. Slide 5: Consumer Health – FY2019 Highlights

    CONSUMER HEALTH – FY2019 HIGHLIGHTS Change AUD$M FY2019 FY2018 • Accelerating underlying sales growth: Underlying consumer health revenue increased year on year by 39%* to $7.34m, up from 25% revenue growth in FY2018, on a like for like basis Consumer Health Revenue 7.34 5.65 up 30% • Improving oper

  6. Slide 6: Consolidated – FY2019 Highlights

    CONSOLIDATED – FY2019 HIGHLIGHTS Change AUD$M FY2019 FY2018 year on year • Strengthened balance sheet: In September 2018, Cellmid completed a $10m capital raise. These funds were used to invest in future growth, repay debt and PROFIT & LOSS liabilities and strengthen the balance sheet Total Reported

  7. Slide 7: Section 2: Consumer Health Segment Reporting

    SECTION 2: CONSUMER HEALTH SEGMENT REPORTING 7

  8. Slide 8: Japan

    JAPAN AUD$M FY2019 FY2018 Change FY2020 Expansion Opportunities Reported Revenue 5.93 4.23 up 40% • évolis® e-commerce: The évolis® e-commerce platform was launched in Japan in August Operating Profit 1.66 0.71 Up 134% 2019 with significant growth potential in FY2020 • Jo-Ju® and Lexilis® e-commerce

  9. Slide 9: Australia

    AUSTRALIA AUD$M FY2019 FY2018 Change FY2020 Expansion Opportunities Reported Revenue 993K 1.21 down 18%* • National distribution partner: Cellmid continues to advance contract negotiations with a Operating Loss (1.5) (1.7) down 12% national distribution partner and plan to finalise a deal in FY2020

  10. Slide 10: USA

    USA AUD$M FY2019 FY2018 Change FY2020 Expansion Opportunities Reported Revenue 0.4 0.2 up 102% • Scaling into existing channels: Roll-out évolis® into additional Neiman Marcus stores Operating Loss (0.9) (0.3) up 220% in FY2020 • Continued expansion of e-commerce: Cellmid continues to invest in its

  11. Slide 11: China

    CHINA FY2019 Highlights • Fukangren, the Group’s exclusive distributor in China for the évolis® branded tonics and shampoos, has been pursuing regulatory submissions for the products since May 2018. Application for the tonics were submitted in early 2019. • Subject to receiving the approvals, Fukang

  12. Slide 12: Section 3: Investing in Future Growth

    SECTION 3: INVESTING IN FUTURE GROWTH 12

  13. Slide 13: Investment in Senior Management in FY2019

    INVESTMENT IN SENIOR MANAGEMENT IN FY2019 * Hired in FY2019 Maria Halasz | CEO and Managing Director Raj Ghatge* | Marketing Director STRATEGY BUSINESS DEVELOPMENT LIFE SCIENCES BRAND BUILDING E-COMMERCE With 24+ years in the sector Maria started in corporate finance specialising in life Raj has ove

  14. Slide 14: Investment in Operations in FY2019

    INVESTMENT IN OPERATIONS IN FY2019 Strategic 1. Diversify Revenue 2. Expand e-commerce 3. Expand leadership 4. Secure supply chain 5. Invest in 6. Prepare for Growth team operational efficiency separation of objectives businesses Continue to expand market Strong focus on building Appointed senior te

  15. Slide 15: Investment in E-commerce in 2HY2019

    INVESTMENT IN E-COMMERCE IN 2HY2019 2HY2019 e-commerce activities: Actioned in 2HY 2019 Partner New commercial platform • In 2HY2019, Cellmid invested in its e-commerce infrastructure and digital marketing capabilities making significant progress Introduced AfterPay • The full benefits of this inves

  16. Slide 16: Investment in Brand Awareness in FY2019

    INVESTMENT IN BRAND AWARENESS IN FY2019 16

  17. Slide 17: Investment in Digital Marketing in FY2019

    INVESTMENT IN DIGITAL MARKETING IN FY2019 Content Is King Retention Brand Strategies Communication Search Engine CRM (database) Optimisation (SEO) Search Engine e-Mail Marketing Marketing (SEM) Socials Lead Generation (FB, IG, YouTube) Facebook Ads 17

  18. Slide 18: Section 4: Lyramid Segment Reporting

    SECTION 4: LYRAMID SEGMENT REPORTING 18

  19. Slide 19: Lyramid – FY2019 Highlights

    LYRAMID – FY2019 HIGHLIGHTS • Consolidation of assets: In preparation for the separation of the biotech and consumer health assets, all midkine related assets and patents were consolidated in a single subsidiary, Lyramid Ltd. • New Lyramid CEO: In June 2019, Cellmid appointed Bart Wuurman as CEO of

  20. Slide 20: Section 5: Upcoming Milestones

    SECTION 5: UPCOMING MILESTONES 20

  21. Slide 21: Upcoming Milestones

    UPCOMING MILESTONES • Distribution agreements in new territories and channels • Expansion of e-commerce in all key markets • European distribution partner sales to commence • Chinese regulatory approval and sales to commence • Chinese distribution of heritage brands to expand • Progress on midkine p

  22. Slide 22: CDY – Focus on Growing Shareholder Value

    CDY – FOCUS ON GROWING SHAREHOLDER VALUE • Accelerating sales and effective cost management expected to deliver operating profitability for the consumer health business in FY2020 • Focus on separating Advangen and Lyramid in FY2020 to unlock shareholder value in both businesses • Strong management t

Cellmid — FY2019 Earnings Presentation on 6ix